Homeopathy and public health: multimorbidity, polypharmacy, antimicrobial resistance, adverse drug reactions and homeopathy

Homeopathy ◽  
2016 ◽  
Vol 105 (1) ◽  
pp. 14
Author(s):  
Peter Fisher
Keyword(s):  
Public Health ◽  
Antimicrobial Resistance ◽  
Adverse Drug Reactions ◽  
Drug Reactions

Pharmacogenetics, Adverse Drug Reactions and Public Health

2006 ◽  
Vol 9 (1) ◽  
pp. 50-54 ◽  
Author(s):  
Regine Kollek ◽  
Jan van Aken ◽  
Günter Feuerstein ◽  
Mechtild Schmedders
Keyword(s):  
Public Health ◽  
Adverse Drug Reactions ◽  
Drug Reactions

scholarly journals The Hospital Antimicrobial Use Process: From Beginning to End

2018 ◽  
Vol 5 (6) ◽  
Author(s):  
William R Truong ◽  
Jason Yamaki
Keyword(s):  
Antimicrobial Resistance ◽  
Patient Outcomes ◽  
Adverse Drug Reactions ◽  
Antimicrobial Stewardship ◽  
Antimicrobial Use ◽  
Drug Reactions ◽  
Improve Patient ◽  
Appropriate Antimicrobial Use

Abstract Hospital antimicrobial stewardship (AMS) programs are responsible for ensuring that all antimicrobials are utilized in the most appropriate and safe manner to improve patient outcomes, prevent adverse drug reactions, and prevent the development of antimicrobial resistance. This Perspectives article outlines the hospital antimicrobial use process (AUP), the foundational system that ensures that all antimicrobials are utilized in the most appropriate and safe manner. The AUP consists of the following steps: antimicrobial ordering, order verification, preparation and delivery, administration, monitoring, and discharge prescribing. AMS programs should determine how each step contributes to how an antimicrobial is used appropriately or inappropriately at their institution. Through this understanding, AMS programs can integrate stewardship activities at each step to ensure that every opportunity is taken to optimize antimicrobial use during a patient’s treatment course. Hence, approaching AMS through the framework of a hospital’s AUP is essential to improving appropriate antimicrobial use.

scholarly journals CHLOROQUINE AND HYDROXYCHLOROQUINE: A MAJOR BREAKTHROUGH FOR COVID-19

2020 ◽  
pp. 1-5
Author(s):  
KRITIKA VERMA ◽  
INDER KUMAR
Keyword(s):  
Public Health ◽  
Side Effects ◽  
Adverse Drug Reactions ◽  
Animal Studies ◽  
Public Health Emergency ◽  
Hydroxyl Group ◽  
Pharmacological Effects ◽  
Global Public Health ◽  
Drug Reactions ◽  
Coronavirus Infection

Coronavirus pandemic or COVID-19 is a global public health emergency at this period. Presently, no pharmacological treatment is known to treat this condition. Hydroxychloroquine (HCQ), a derivative of chloroquine (CQ), was first synthesized in 1946 by adding a hydroxyl group to CQ, which is much less toxic than CQ in animal studies. Other than being an anti-malarial drug, it was revealed to have various pharmacological effects and one of those is its anti-viral property. CQ, as well as HCQ, has been used in SARS (Severe Acute Respiratory Syndrome) coronavirus infection due to its antiviral properties. Even though various scientists have considered HCQ as a better therapeutic approach than CQ for the treatment of coronavirus infection, there are various adverse drug reactions associated with HCQ treatment in COVID-19 patients. In this paper, we review the anti-viral mechanism, various adverse drug reactions, and side effects of HCQ for COVID-19 treatment.

Assessment of the impact of the Scottish public health campaign on patient reporting of adverse drug reactions

2016 ◽  
Vol 32 (5) ◽  
pp. 209-218
Author(s):  
Mamoon A. Aldeyab ◽  
Sheila C. Noble ◽  
Melinda Cuthbert ◽  
Simon Maxwell ◽  
James Dear ◽  
...  
Keyword(s):  
Public Health ◽  
Adverse Drug Reactions ◽  
Patient Reporting ◽  
Drug Reactions ◽  
Public Health Campaign ◽  
Health Campaign ◽  
The Impact

scholarly journals Biological drugs for the treatment of psoriasis in a public health system

2014 ◽  
Vol 48 (4) ◽  
pp. 651-661 ◽  
Author(s):  
Luciane Cruz Lopes ◽  
Miriam Sanches do Nascimento Silveira ◽  
Iara Alves de Camargo ◽  
Silvio Barberato-Filho ◽  
Fernando de Sá Del Fiol ◽  
...  
Keyword(s):  
Public Health ◽  
Health System ◽  
Adverse Drug Reactions ◽  
Public Health System ◽  
Judicial System ◽  
High Rate ◽  
Clinical Monitoring ◽  
Legal Action ◽  
Drug Reactions ◽  
Biological Drugs

OBJECTIVE To analyze the access and utilization profile of biological medications for psoriasis provided by the judicial system in Brazil.METHODSThis is a cross-sectional study. We interviewed a total of 203 patients with psoriasis who were on biological medications obtained by the judicial system of the State of Sao Paulo, from 2004 to 2010. Sociodemographics, medical, and political-administrative characteristics were complemented with data obtained from dispensation orders that included biological medications to treat psoriasis and the legal actions involved. The data was analyzed using an electronic data base and shown as simple variable frequencies. The prescriptions contained in the lawsuits were analyzed according to legal provisions.RESULTS A total of 190 lawsuits requesting several biological drugs (adalimumab, efalizumab, etanercept, and infliximab) were analyzed. Patients obtained these medications as a result of injunctions (59.5%) or without having ever demanded biological medication from any health institution (86.2%), i.e., public or private health services. They used the prerogative of free legal aid (72.6%), even though they were represented by private lawyers (91.1%) and treated in private facilities (69.5%). Most of the patients used a biological medication for more than 13 months (66.0%), and some patients were undergoing treatment with this medication when interviewed (44.9%). Approximately one third of the patients discontinued treatment due to worsening of their illness (26.6%), adverse drug reactions (20.5%), lack of efficacy, or because the doctor discontinued this medication (13.8%). None of the analyzed medical prescriptions matched the legal prescribing requirements. Clinical monitoring results showed that 70.3% of the patients had not undergone laboratory examinations (blood work, liver and kidney function tests) for treatment control purposes.CONCLUSIONS The plaintiffs resorted to legal action to get access to biological medications because they were either unaware or had difficulty in accessing them through institutional public health system procedures. Access by means of legal action facilitated long-term use of this type of medication through irregular prescriptions and led to a high rate of adverse drug reactions as well as inappropriate clinical monitoring.

Sign in / Sign up

Export Citation Format

Share Document